Clinical Research Details Clinical Research BIPI Protocols 1199.247: A Double-blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52-weeks in Patients with Progressive Fibrosing Interstital Lung Disease (PF-ILD) Study Description This study is being done to: 1.see how well the study drug, called nintedanib, may help your lung disease. 2.compare the safety and effects of nintedanib with a placebo in subjects with PF-ILD. Investigators Principal Investigator Lisa M. Jones, M.D. Medicine Sub Investigator James D. Cury, M.D. Medicine Sub Investigator Mariam Louis, M.D. Medicine Sub Investigator Vandana K. Seeram, M.B.B.S. (M.D.) Medicine